We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current EVLO market cap is 9.49k. The company's latest EPS is USD -6.0332 and P/E is -0.05.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -58.1M | -86.36M | -91.89M | -115.4M | -108.47M |
| Net Income | -60.88M | -85.47M | -93.67M | -122.18M | -114.53M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 159.87M | 90.92M | 90.64M | 87.87M | 64.44M |
| Total Liabilities | 22.92M | 30.72M | 60.15M | 79.2M | 69.43M |
| Total Equity | 136.95M | 60.2M | 30.49M | 8.67M | -4.99M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -47.28M | -71.98M | -73.06M | -96.73M | -101.24M |
| Investing | -60.13M | 51.97M | -1.32M | -1.48M | -622k |
| Financing | 162.01M | 4.99M | 65.47M | 97.54M | 81.66M |
| Market Cap | 9.49k |
| Price to Earnings Ratio | -0.05 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.13 |
| Price to Book Ratio | -1.22 |
| Dividend Yield | - |
| Shares Outstanding | 18.98M |
| Average Volume (1 week) | 5.78k |
| Average Volume (1 Month) | 2.47k |
| 52 Week Change | -99.09% |
| 52 Week High | 0.075 |
| 52 Week Low | 0.0001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Evelo Biosciences Inc (CE) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.evelobio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
